Comparison of the in vitro cytotoxicity of hydroxylamine metabolites of sulfamethoxazole and dapsone.
The differential incidence of adverse drug reactions (ADR) between trimethoprim-sulfamethoxazole and dapsone might be explained, in part, by differences in the inherent toxicity of the hydroxylamine metabolites of sulfamethoxazole and dapsone. To test this hypothesis, the in vitro cytotoxicities of sulfamethoxazole hydroxylamine, dapsone hydroxylamine, and monoacetyldapsone hydroxylamine were compared using peripheral blood mononuclear cells (PBMC) from healthy volunteers. After 3 hr of exposure to hydroxylamine metabolites, PBMC were washed thoroughly to remove residual hydroxylamine, and viability was assessed 16 hr later by determination of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) conversion. A concentration-dependent toxicity was observed with each hydroxylamine metabolite. While dapsone hydroxylamine and monoacetyldapsone hydroxylamine were not significantly different, both showed significantly greater cytotoxic potency than sulfamethoxazole hydroxylamine (P < 0.05). This differential potency was not a function of differential stability in aqueous medium and was maintained over time. The effects of red blood cells (RBC), impermeable RBC "ghosts," and RBC lysate on hydroxylamine-induced cytotoxicity were determined using a two-compartment dialysis system. Amelioration of hydroxylamine-dependent cytotoxicity occurred when RBC were included in PBMC incubations. This apparent detoxifying effect was markedly greater using RBC lysate in comparison with impermeable "ghosts" (P < 0.05). No difference in detoxification was observed between sulfamethoxazole hydroxylamine and monoacetyldapsone hydroxylamine. Differences in the inherent cytotoxicity of their hydroxylamine metabolites do not appear to explain the differential incidence of ADR between trimethoprim-sulfamethoxazole and dapsone.
Reilly
T P
TP
Department of Pharmaceutical Sciences, Wayne State University, Detroit, MI 48202, USA.
Bellevue
F H
FH
Woster
P M
PM
Svensson
C K
CK
D002470:Cell Survival / Q000187:drug effects; D003622:Dapsone / Q000009:adverse effects* / Q000378:metabolism; D004342:Drug Hypersensitivity / Q000209:etiology*; D004912:Erythrocytes / Q000502:physiology; D006801:Humans; D019811:Hydroxylamine / Q000009:adverse effects*; D066298:In Vitro Techniques; D007963:Leukocytes, Mononuclear / Q000187:drug effects; D016014:Linear Models; D016015:Logistic Models; D013420:Sulfamethoxazole / Q000009:adverse effects* / Q000378:metabolism
D019811:Hydroxylamine; D003622:Dapsone; D013420:Sulfamethoxazole